Volume 2011, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426


In our study we present two cases that have been diagnosed as stage I endometrial carcinoma where a Levonorgestrel intrauterine releasing system (LNG-IUS) referred to as Mirena was used as a primary treatment because the standard surgical treatment was deemed to carry an unacceptable risk of death. Histopathology report after therapy showed complete regression of endometrial cancer.


Article metrics loading...

Loading full text...

Full text loading...


  1.   Levonorgestrel intro-uterine system for menorrhagio. Drug Ther Bull. 2001; 39::8587.
    [Google Scholar]
  2. Abu J, Brown L, Ireland D. Endometrial adenocarcinoma following insertion of the levonorgestrel - Releasing intra-uterine system (Mirena) in a 36 year old woman. Inter J Gyn Cancer. 2006; 16::14391478.
    [Google Scholar]
  3. Theodoros G, Simon BM, Anil T. Levonorgestrel releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004; 95::762764.
    [Google Scholar]
  4. Martin-Hirch PL, Jarvis G. Progestogens for endometrial cancer (Cochran Review) In: The Cochrane Library. 2004; Issue 2.
  5. Phillips V, Graham CT. The effects of the Levonorgestrel intrauterine system (Mirena Coil) on endometrial morphology.
  6. Nilsson CG, Houkkamaa M. Tissue concentrations of Levonorgestrel in women using a Levonorgestrel IUD. Clin Endocrinol. 1982; 17::529536.
    [Google Scholar]
  7. Anderson JK, Rybo G. Levonorgestrel releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynecol. 1990; 97::690694.
    [Google Scholar]
  8. Hurskainen R, Paavonen J. Levonorgestrel releasing intrauterine system in the treatment of heavy menstrual bleeding. CurrOpin Obstet Gynecol. 2004; 16::487490.
    [Google Scholar]
  9. Hurskainen R, Teperi J, Aalto AM. Levonorgestrel releasing intrauterine system or hysterectomy in the treatment of essential menorrhagia: predictors of outcome'Acta Obstet Gynaecol. Scand. 2004; 83::401403.
    [Google Scholar]
  10. Critchley HO, Wang H, Jones RL. Morphological and functional features of endometrial decidualization following long- term intrauterine levonorgestrel delivery. Hum Reprod. 1998; 13::12181224.
    [Google Scholar]
  11. Maruo T, Ladag-Fernandez JB, Pakarinen P. Effects of the Levonorgestrel releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod. 2001; 16::21032108.
    [Google Scholar]
  12. Zalel Y, Shulman A, Lidor A. The local progestational effect of the Levonorgestrel releasing intrauterine system: a sonographic and Doppler flow study. Human Reprod. 2002; 17::28782880.
    [Google Scholar]
  13. Bahamondes L, Ribeiro-Huguet P, de Andrade KC. Levonorgestrel releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand. 2003; 82::580582.
    [Google Scholar]
  14. Grander FJ, Konje JC, Abrams KR. Endometrial protection from tamoxifen stimulated changes by a Levonorgestrel releasing intrauterine system: A randomized controlled trial. Lancet. 2000; 356::17111717.
    [Google Scholar]
  15. Vereide AB, Ames M, Straume B. Nuclear morphometric changes and therapy monitoring in patients with endometrial (hyperplasia: A study comparing effects of intrauterine levonorgestrel and systemic medroxyprogestrone. Gynecol Oncol. 2003; 91:3:526533.
    [Google Scholar]
  16. References from up to date [1] Endometrial cancer: Clinical features, diagnosis, and screening, [46], page 24 of 33.
  17. References from up to date [11,12] Endometrial cancer: Clinical features, diagnosis,and screening, page 3 of 33.
  18. From clinics in obstetrics and gynecology [13], December 1986, endometrial cancer, WTCREASMAN, page 690-691.
  • Article Type: Case Report
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error